![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Active Filter(s):
Details:
The stability and efficacy of MTX-101 (IPA-3), are significantly superior in inhibiting prostate tumor growth and metastasis in various mouse models of prostate cancer and demonstrate broad applicability across solid tumor cancers.
Lead Product(s): IPA-3
Therapeutic Area: Oncology Product Name: MTX-101
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: J-Star Research
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 07, 2022